[{"id":"06e9e816-ed4d-495d-af8e-3454497c5c2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00194714","created_at":"2021-01-18T00:39:44.293Z","updated_at":"2024-07-02T16:34:37.821Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab","source_id_and_acronym":"NCT00194714","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 expression • HLA-A2 positive","tags":["HER-2 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • HER-2/neu peptide vaccine"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 05/22/2023","study_completion_date":" 05/22/2023","last_update_posted":"2024-06-06"},{"id":"d62c1b12-231e-41f3-9f47-89579c4ab1f5","acronym":"ACCRU-BR-1701","url":"https://clinicaltrials.gov/study/NCT04197687","created_at":"2021-01-18T20:27:24.447Z","updated_at":"2025-02-25T13:53:04.701Z","phase":"Phase 2","brief_title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","source_id_and_acronym":"NCT04197687 - ACCRU-BR-1701","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • HER-2/neu peptide vaccine • Leukine (sargramostim) • TPIV100"],"overall_status":"Recruiting","enrollment":" Enrollment 480","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-12-18"},{"id":"7ec4dc43-23fc-4cf6-bad6-c9e36b3d162c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01355393","created_at":"2021-01-18T05:32:33.668Z","updated_at":"2024-07-02T16:36:50.276Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer","source_id_and_acronym":"NCT01355393","lead_sponsor":"University of Washington","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ampligen (rintatolimod) • HER-2/neu peptide vaccine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":"","study_completion_date":"","last_update_posted":"2020-02-10"},{"id":"a3660b0c-6ed3-4249-9b3d-fdf23e01573d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00640861","created_at":"2021-01-18T02:23:05.773Z","updated_at":"2024-07-02T16:37:05.719Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer","source_id_and_acronym":"NCT00640861","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • CD8 • IFNG • MUC1 • CD4 • IL5","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • PGR expression • HLA-A2 positive","tags":["HER-2 • CD8 • IFNG • MUC1 • CD4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • PGR expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2/neu peptide vaccine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 08/28/2008","start_date":" 08/28/2008","primary_txt":" Primary completion: 04/21/2015","primary_completion_date":" 04/21/2015","study_txt":" Completion: 04/21/2015","study_completion_date":" 04/21/2015","last_update_posted":"2018-10-31"},{"id":"1cf91864-ed97-4bcc-82ac-babbd65f364d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923143","created_at":"2021-01-18T03:34:23.915Z","updated_at":"2024-07-02T16:37:17.369Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Treating Patients With Ductal Carcinoma In Situ of the Breast","source_id_and_acronym":"NCT00923143","lead_sponsor":"University of Pennsylvania","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2/neu peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-03"},{"id":"495cb1bd-cd29-44f5-9be4-e00fda829d84","acronym":"","url":"https://clinicaltrials.gov/study/NCT00791037","created_at":"2021-01-18T03:00:07.455Z","updated_at":"2024-07-02T16:37:21.728Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Treating Patients With Stage IV Breast Cancer","source_id_and_acronym":"NCT00791037","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG • CD4","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • HER-2/neu peptide vaccine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2017-05-25"}]